LyudmilaA.BazhenovaMD

Oncology • La Jolla, CA

Thoracic Cancer

Moores UCSD Cancer Center

Join to view full profile

Dr. Bazhenova is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Bazhenova's full profile

Already have an account?

Office
3855 Health Sciences Drive, MC 0987
La Jolla, CA 92037
Phone+1 858-822-6189

Fax+1 858-822-6190
Is this information wrong?

Summary

I am a Clinical Professor of Medicine at UC San Diego Moores Cancer Center, Lung Cancer Unit Leader and a Director of the Hematology Oncology training program. My clinical practice and research concentrate on lung cancer. I have vast experience in clinical trial management, design and implementation. I serve as Chair of UC San Diego Protocol Review and Monitoring committee. I an a member of Alliance Respiratory Committee. I am a recipient of NCI Clinical Trial Leadership Award, San Diego Best Doctors awards and Women Who Mean Business Award. My main research interest is drug development.
I completed my M.D. at Nizhny Novgorod State Medical Academy in Nizhny Novgorod, Russia. I graduated from Internal medicine residency at University of California Los Angeles/ West Los Angeles VA medical center and then completed a fellowship in Hematology-Oncology at Scripps-Green Hospital in La Jolla in 2005 and have been in practice at NCI designated UC San Diego Moores Cancer Center since 2005.

Education & Training

Scripps Clinic/Scripps Green HospitalFellowship, Hematology and Medical Oncology, 2002 - 2005
UCLA-VA Greater Los AngelesResidency, Internal Medicine, 1999 - 2002
Nizhny Novgorod State Medical Academy Class of 1994

Certifications & Licensure

CA State Medical License 2001 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Super Doctor SuperDoctors.com

Clinical Trials

Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer Start of enrollment: 2007 Sep 01
Terminated
Phase 2
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer Start of enrollment: 2011 May 01
Completed
Phase 2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113) Start of enrollment: 2011 Sep 20
Completed
Phase 1, Phase 2
LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib Start of enrollment: 2012 Nov 26
Completed
Phase 2
LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer Start of enrollment: 2012 Dec 20
Completed
Phase 2
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
Circulating Tumor Cells in Non-Small Cell Lung Carcinoma Start of enrollment: 2012 Nov 01
Completed
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Completed
Phase 2
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
No longer available
A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib Start of enrollment: 2014 Jun 04
Completed
Phase 2
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
Active, not recruiting
Phase 3
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors Start of enrollment: 2017 Feb 23
Terminated
Phase 1
Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2016 Aug 29
Active, not recruiting
Phase 1
Roles: Contact, Sponsor-Investigator, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3.
Owen, D. H., Ishmael A Jaiyesimi, Natasha B Leighl, Nofisat Ismaila, Krishna Alluri, Narjust Florez, Shirish Gadgeel, Gregory Masters, Erin L Schenk, Bryan J Schneider...> ;Journal of Clinical Oncology. 2024 Apr 10
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3.
Owen, D. H., Ishmael A Jaiyesimi, Natasha B Leighl, Nofisat Ismaila, Krishna Alluri, Narjust Florez, Shirish Gadgeel, Gregory Masters, Erin L Schenk, Bryan J Schneider...> ;Journal of Clinical Oncology. 2024 Apr 10
Multi-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I trial.
Parra, E., Zhang, J., Duose, D., Gonzalez-Kozlova, E., Redman, M., Chen, H., Manyam, G., Kumar, G., Zhang, J., Song, X., Lazcano, R., Marques-Piubelli, M., Laberiano-F...> ;Clinical Cancer Research. 2024 Jan 26
Repotrectinib in a Patient WithFusion-Positive Pancreatic Carcinoma and Congenital Long QT Syndrome.
Velasco, K., Yun, K., Narezkina, A., Redfern, C., Bazhenova, L.> ;JCO Precision Oncology. 2024 Jan 1
1 citations
ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study.
Michelle Wang, Shadera Slatter, Jesse Sussell, Chia-Wei Lin, Sarika Ogale, Debajyoti Datta, Atul J Butte, Lyudmila Bazhenova, Vivek A Rudrapatna> ;Targeted Oncology. 2023 Jul 1
Metastatic-amplified non-small-cell lung cancer treated with trastuzumab deruxtecan.
Karen M Yun, Lyudmila Bazhenova> ;BMJ Case Reports. 2023 May 8
1 citations
Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG).
Shing M Lee, Weijia Fan, Aijin Wang, Riha Vaidya, Mary W Redman, Scott N Gettinger, Lyudmila Bazhenova, Roy S Herbst, Dawn L Hershman, Joseph M Unger> ;JCO Clinical Cancer Informatics. 2023 Apr 1
4 citations
Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib.
Jun Zhang, Melissa Johnson, Minal Barve, Lyudmila Bazhenova, Marybeth McCarthy, Rowena Schwartz, Elise Horvath-Walsh, Karen Velastegui, Chunlin Qian, Alexander Spira> ;The Oncologist. 2023 Apr 6
Management of toxicities associated with immune checkpoint inhibitors.
Karen M Yun, Lyudmila Bazhenova> ;Clinical Advances in Hematology & Oncology. 2023 Mar 1
8 citations
Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real-world genomic datasets.
Santiago Viteri, Anna Minchom, Lyudmila Bazhenova, Sai-Hong Ignatius Ou, Joshua M Bauml, Scott A Shell, Michael Schaffer, Junchen Gu, Jennifer B Rose, Joshua C Curtin,...> ;Molecular Oncology. 2023 Feb 1
2 citations
Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I.
Joseph M Unger, Lu Qian, Mary W Redman, Susan S Tavernier, Lori Minasian, Ellen V Sigal, Vassiliki A Papadimitrakopoulou, Michael Leblanc, Charles S Cleeland, Samuel A...> ;Journal of the National Cancer Institute. 2023 Apr 11
2 citations
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment forexon 20 insertion-positive non-small cell lung cancer.
James Chih-Hsin Yang, Caicun Zhou, Pasi A Jänne, Suresh S Ramalingam, Tae Min Kim, Gregory J Riely, Alexander I Spira, Zofia Piotrowska, Tarek Mekhail, Maria Rosario G...> ;Expert Review of Anticancer Therapy. 2023 Jan 1
9 citations
Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors.
Christian Kollmannsberger, Herbert Hurwitz, Lyudmila Bazhenova, Byoung Chul Cho, David Hong, Keunchil Park, Karen L Reckamp, Sunil Sharma, Hirak Der-Torossian, James G...> ;Targeted Oncology. 2023 Jan 1
16 citations
First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors.
Todd Bauer, Byong Chul Cho, Rebecca Heist, Lyudmila Bazhenova, Theresa Werner, Sanjay Goel, Dong-Wan Kim, Douglas Adkins, Richard D Carvajal, Ajjai Alva, Keith Eaton, ...> ;Investigational New Drugs. 2022 Oct 1
2 citations
Real-world observational study of current treatment patterns and outcomes in recurrent or locally advanced/metastatic non-small cell lung cancer.
Lyudmila Bazhenova, Jonathan Kish, Beilei Cai, Nydia Caro, Bruce Feinberg> ;Cancer Treatment and Research Communications. 2022 Jan 1
6 citations
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials.
Scott N Gettinger, Rudolf M Huber, Dong-Wan Kim, Lyudmila Bazhenova, Karin Holmskov Hansen, Marcello Tiseo, Corey J Langer, Luis G Paz-Ares Rodríguez, Howard L West, K...> ;JTO Clinical and Research Reports. 2022 Sep 1
2 citations
Prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100,000 genomes project.
John Bridgewater, Xiaolong Jiao, Mounika Parimi, Clare Flach, Jeran Stratford, Atanas Kamburov, Arndt A Schmitz, Jihong Zong, John A Reeves, Karen Keating, Amanda Brun...> ;Cancer Treatment and Research Communications. 2022 Jan 1
90 citations
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With AdvancedSolid Tumors (KRYSTAL-1).
Sai-Hong Ignatius Ou, Pasi A Jänne, Ticiana A Leal, Igor I Rybkin, Joshua K Sabari, Minal A Barve, Lyudmila Bazhenova, Melissa L Johnson, Karen L Velastegui, Cornelius...> ;Journal of Clinical Oncology. 2022 Aug 10
Resistance to EGFR Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer via Newly Acquired Targetable Oncogenic Driver Alterations With an Emphasis on: Case...
Nicholas P Giustini, Sandip Pravin Patel, Nathaniel J Myall, José Fernando do Prado Moura, Amit Kulkarni, Richard C Chao, Heather Wakelee, Lyudmila Bazhenova> ;JCO Precision Oncology. 2022 Aug 1
6 citations
Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors.
Nicolas Girard, Anna Minchom, Sai-Hong Ignatius Ou, Shirish M Gadgeel, José Trigo, Santiago Viteri, Joshua M Bauml, Anil Londhe, Parthiv Mahadevia, Lyudmila Bazhenova> ;Clinical Lung Cancer. 2022 Nov 1
187 citations
Adagrasib in Non-Small-Cell Lung Cancer Harboring aMutation.
Pasi A Jänne, Gregory J Riely, Shirish M Gadgeel, Rebecca S Heist, Sai-Hong I Ou, Jose M Pacheco, Melissa L Johnson, Joshua K Sabari, Konstantinos Leventakos, Edwin Ya...> ;The New England Journal of Medicine. 2022 Jul 14
3 citations
A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer.
Benjamin Solomon, Ana Callejo, Jair Bar, Guy Berchem, Lyudmila Bazhenova, Pierre Saintigny, Fanny Wunder, Jacques Raynaud, Nicolas Girard, J Jack Lee, Raed Sulaiman, B...> ;Cancer Medicine. 2022 Jul 1
13 citations
Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after pla...
Anna Minchom, Santiago Viteri, Lyudmila Bazhenova, Shirish M Gadgeel, Sai-Hong Ignatius Ou, José Trigo, Joshua M Bauml, Daniel Backenroth, Archan Bhattacharya, Tracy L...> ;Lung Cancer. 2022 Jun 1
1 citations
Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors.
Demetri, G., De Braud, F., Drilon, A., Siena, S., Patel, M., Cho, B., Liu, S., Ahn, M., Chiu, C., Lin, J., Goto, K., Lee, J., Bazhenova, L., John, T., Fakih, M., Chawl...> ;Clinical Cancer Research. 2022 May 13
21 citations
Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
Mengzhao Wang, James Chih-Hsin Yang, Paul L Mitchell, Jian Fang, D Ross Camidge, Weiqi Nian, Chao-Hua Chiu, Jianying Zhou, Yanqiu Zhao, Wu-Chou Su, Tsung-Ying Yang, Vi...> ;Cancer Discovery. 2022 Jul 6
Join now to see all

Lectures

A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biom...
2019 ASCO Annual Meeting - 6/1/2019

Authored Content

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020

Press Mentions

Cancer Status Report: Overall Death Rate Continues to DropJanuary 15th, 2022
Lung-MAP: A Five-Year Recap on the First Master Protocol Trial in Cancer ResearchFebruary 21st, 2020
Breathing in Life with Stage IV Lung CancerNovember 26th, 2019
Join now to see all